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Background: AirSeal™ is a novel class of valve-free insufflation system that enables a stable pneumoperitoneum
with continuous smoke evacuation and carbon dioxide (CO2) recirculation during laparoscopic surgery. Comparison
data to standard CO2 pressure pneumoperitoneum insufflators is scarce. The aim of this study is to evaluate the
potential advantages of AirSeal™ compared to a standard CO2 insufflator.
Methods/Design: This is a single center randomized controlled trial comparing elective laparoscopic
cholecystectomy, colorectal surgery and hernia repair with AirSeal™ (group A) versus a standard CO2 pressure
insufflator (group S). Patients are randomized using a web-based central randomization and registration system.
Primary outcome measures will be operative time and level of postoperative shoulder pain by using the visual
analog score (VAS). Secondary outcomes include the evaluation of immunological values through blood tests,
anesthesiological parameters, surgical side effects and length of hospital stay. Taking into account an expected
dropout rate of 5%, the total number of patients is 182 (n = 91 per group). All tests will be two-sided with a
confidence level of 95% (P <0.05).
Discussion: The duration of an operation is an important factor in reducing the patient’s exposure to CO2
pneumoperitoneum and its adverse consequences. This trial will help to evaluate if the announced advantages
of AirSeal™, such as clear sight of the operative site and an exceptionally stable working environment, will facilitate
the course of selected procedures and influence operation time and patients clinical outcome.
Trial registration: ClinicalTrials.gov NCT01740011, registered 23 November 2012.
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Laparoscopic surgery is currently actively used in a var-
iety of surgical conditions and is performed through the
creation of a workspace between the abdominal wall and
the internal organs, most commonly by the insufflation
of carbon dioxide (CO2) to the level of positive intra-
abdominal pressure tolerated by the patient. CO2 is the
most frequent employed medium because it is relatively
inexpensive, colorless, odorless, nonflammable and rap-
idly eliminated from systemic circulation [1,2]. A good* Correspondence: ruzica-rosalia.luketina@bhs.at
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unless otherwise stated.exposure to the operative field facilitates an improved
technical performance and is a factor that affects the
duration of an operation and the safety of a patient
during the course of the procedure. Conventional CO2
insufflation systems often respond with a delay to in-
creased intraoperative pressure loss. The collapse of the
abdominal cavity during increased systemic absorption
of CO2 gas, for example as a result of suction or smoke
evacuation, may prolong operation time and can be pre-
vented only by an increase in CO2 insufflation pressure.
The CO2 and higher abdominal pressure adversely
affects the patient’s homeostasis, causing significant
changes in cardiovascular and respiratory systems, de-
creasing perfusion in abdominal organs and blood flowl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
• Aged 18 years and over • Previous extensive abdominal
surgery
• ASA ≤ 3 • Acute surgical intervention
• Informed consent provided • Immunological dysfunctions
like advanced liver disease,
HIV or hepatitis C virus infection
• Diseases of the gallbladder, colon or
hernias treated with elective
laparoscopic procedure
• Pregnancy and lactation
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thrombotic disease [3].
Insufflation of CO2 during laparoscopic surgery leads
to postoperative shoulder pain. The origin of shoulder
pain is commonly assumed to be due to the overstretch-
ing of the diaphragmatic muscle fibres owing to a high
CO2 pressure [4]. The physiology of the pneumoperito-
neum is complex with local and systemic effects of a gas
instilled under pressure [5]. It has been proven that
surgical trauma is connected with the changes in cytokine
concentration. Excessive production of pro-inflammatory
cytokines after surgical procedures may have an unfavor-
able influence on the healing process and cause complica-
tion during postoperative period. Many physiological
changes of laparoscopic surgery have recently been
reported in research articles [6-8]. Among these studies, it
has been theorized that conventional laparoscopic surgery
under CO2 gas is immunologically superior to laparotomy
[9]. Substantial experimental and clinical evidence also
exists indicating that the immune response is better pre-
served after laparoscopic surgery [9-14], but the mecha-
nism for immune system preservation under the CO2
gas-specific effect is still unclear in all situations. To exam-
ine changes in the concentrations of certain cytokines and
angiogenic factors serum levels in the early postoperative
period after laparoscopic surgery further studies are needed.
Additionally, the absorption of CO2 during pneumoperito-
neum can lead to an increase in PaCO2 level, however hy-
percapnia is commonly avoided by appropriate ventilatory
changes. Absorption of CO2 also alters the acid–base
balance and the increase in CO2 excretion load. Compared
with baseline values, the increased intra-abdominal pres-
sure during pneumoperitoneum can reduce femoral venous
flow, intraoperative urine output, portal venous flow,
respiratory compliance and cardiac output [3].
Recently, with AirSeal™, a novel class of valve and
membrane-free insufflation and/or trocar system is avail-
able that responds immediately to the slightest changes
in intra-abdominal pressure, maintaining a stable pneu-
moperitoneum and continuous smoke evacuation even
under difficult surgical conditions and constant suction,
ensuring visibility. This insufflation system is associated
with reduced CO2 use, absorption and elimination. Al-
though the reduction of CO2 absorption makes this new
insufflation system an attractive alternative to standard
insufflation systems, to the best of our knowledge, no
randomized clinical studies have been performed which
characterize the potential benefits and advantages in order
to demonstrate significant clinical findings until now.
Methods/Design
Objectives and hypotheses
The primary objective of the present randomized trial is
to investigate the mean operative time and to study thefrequency and intensity of postoperative shoulder pain in
patients undergoing laparoscopic cholecystectomy, colorec-
tal surgery, and hernia repair with AirSeal™ (group A) com-
pared with a standard pressure CO2 insufflator (group S).
The first primary endpoint will be whether the time of
surgery in group A is more than or equal to the time of
surgery in group S (H0PE1) or whether the time of sur-
gery in group A is less than the time of surgery in group
S (H1PE1).
The second primary endpoint will be whether shoulder
pain in group A is more than or equal to shoulder pain
in group S (H0PE2) or whether shoulder pain in group A
is less than shoulder pain in group S (H1PE2).
Study population and location
The study population will consist of patients undergoing
elective laparoscopic cholecystectomy, colorectal surgery and
hernia repair. A clinical evaluation and pre-randomization
assessment must be completed for every patient, including
a review of the eligibility criteria, signed and dated in-
formed consent, inquiry of relevant past medical history
and anesthesiological preoperative assessment including
American Society of Anesthesiologists (ASA) class. Drop-
out criteria will be if patients recruited for laparoscopic
resection are converted to an open procedure. Detailed
eligibility criteria are listed in Table 1.
Patients who meet the eligibility criteria will be given a
patient information sheet and time to consider the trial.
If interested, informed consent will be obtained for each
patient prior to randomization. All personal information
obtained for the study will be held securely and treated
as strictly confidential.
This single centre trial will be performed at a high vo-
lume institution with experience in laparoscopic surgery
(Department of General and Visceral Surgery, Sisters of
Charity Hospital Linz, Austria). The clinical study centre
of the surgical department will conduct this trial.
Study design and randomization
After screening for eligibility is performed and informed
consent is obtained, patients will be randomly stratified
regarding type of operation in a 1:1 ratio into one of
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an AirSeal™ CO2 pressure insufflator (Surgiquest Inc.,
Milford, USA) (group A, experimental arm) or laparo-
scopic surgery with a standard CO2 pressure insufflator
(Olympus America Inc. UHI-3, Center Valley, PA, US)
(group S, control arm).
Patients are randomized using a web-based, central
randomization and registration system. Treatment
according to randomization (operation with AirSeal™ or
standard CO2 pressure pneumoperitoneum) must be
carried out within 14 days after randomization. For the
study flow of the trial according to CONSORT guide-
lines, please see Additional file 1.
Primary endpoints
Operation time, defined as the time from skin incision to
closure of wound in minutes, is routinely documented in
our operation program and will be evaluated after the op-
eration by a newly designed survey. Postoperative shoulder
pain will be assessed within 48 hours after the operation
using the visual analogue pain scale (VAS). Postoperative
pain will be assessed in a double-blinded manner, neither
the patient, the assessor of shoulder pain, nor the post-
operative caregivers will be aware of the technique to
which the patient will been randomized.
Secondary endpoints
Blood sample remains will be collected during routinely
preformed venepuncture prior to surgery, intraopera-
tively after pneumoperitoneum skin incision, after skin
suture and 24 hours postoperatively. They will be kept
and used for immunological evaluation. All routine la-
boratory diagnostics will be performed immediately after
blood collection. For the determination of the target pa-
rameters the EDTA (Ethylenediaminetetraacetic acid)
plasma must be frozen by -80°C. All interleukins and
cytokines will be measured at the end of patient recruit-
ment in one sequence. Blood gas analysis and documen-
tation of the ventilation volume will be performed. This
intraoperative data will be also collected by the survey.
Analgetic requirements, wound infections, anastomotic
leakage and postoperative hemorrhage of all the patients
in the postoperative period and length of hospital stay
will be also recorded.
The immunological aspects will be: changes in the
concentration of certain cytokines and angiogenic fac-
tors serum levels in the early postoperative period, and
target parameters (soluble interleukin-1 receptor family
member ST2 (sST2), interleukin (IL)-6, IL-8, IL-10,
vascular endothelial growth factor A (VEGF-A) and
endostatin).
The anesthesiological aspects will be: tidal volume,
positive end expiratory pressure (PEEP), peak pressure,
respiratory minute volume, acid–base balance and CO2elimination in the patients, measured before insufflation, dur-
ing surgery and after deflation of the pneumoperitoneum.
Operative procedure
All patients will be anesthetized following a strict proto-
col for premedication, anaesthesia and intubation as well
as mechanical ventilation and monitoring for CO2 level.
The operation will be performed by experienced staff
surgeons involved in the study. In all patients, access will
be achieved using four working ports and the same in-
struments. In group A, one 5 mm AirSeal™ access port
will be used instead of one standard 5 mm port. Pneu-
moperitoneum will be created without a visual control
using aVeress needle (Ethicon Endo Surgery Inc., Cincinnati,
US) for insertion through a small skin incision in the
umbilical region. Intraperitoneal pressure using CO2 gas
should be kept at around 12 mmHg. The patient should be
placed in a reverse Trendelenburg position with left side
down. Residual CO2 pneumoperitoneum will be evacuated
at the end of the procedure by compressing the abdomen
whilst taking care to keep the valve of the trocar open.
Data collection
Daily visits with study patients will be done by the cli-
nical investigator to collect information on primary and
secondary outcome parameters. A detailed database will
be collected, including sex, age and body mass index
(BMI), ASA grade, medical history prior to operation,
quality of surgical field exposure, duration of surgery
and postoperative shoulder and other pain VAS score.
The number of intravenous and oral medications re-
quired, use of drainage and other intraoperative and
postoperative events in all patients will be recorded as
well as length of hospital stay. All routine blood parame-
ters and blood gas analysis data will be saved. Table 2
summarizes the course of examination and data collec-
tion process.
Ethical considerations
Prior to the start of the trial, protocol written approval
was authorized by the local ethical committee of the
Hospital of the Sisters of Charity in Linz, a member of
the independent Ethics Committee (IEC) of Austria
(Study number: 28/12 AirSeal™ Trial).
Following IEC approval, all subsequent protocol amend-
ments and changes to the informed consent document
must be approved by the responsible IEC. The IEC must
be informed of the end of the trial. The investigator must
keep a record of all communications with the IEC and the
regulatory authorities.
Patients’ confidentiality
It is the responsibility of the investigator to maintain
patient confidentiality. During the trial patients will be
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individual identification code (screening number plus
randomization number). Trial findings will be stored in
accordance with local data protection law and ICH GCP
(International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use provide a unified standard for the European
Union, Japan, and the United States to facilitate the mutual
acceptance of clinical data by the regulatory authorities in
these jurisdictions) guidelines and will be handled in strictest
confidence. The investigator will maintain a personal subject
identification list (screening numbers with the correspon-
ding subject name) to enable records to be identified.
Patient protection
The responsible investigator will ensure that this study is
conducted in agreement with the Declaration of Helsinki
(Tokyo, Venice, Hong Kong, Somerset West and Edinburgh
amendments).
Informed consent
All patients recruited for the study will be informed of the
aims of the study, collection of blood sample remains taken
during routine pre- and postoperative venepuncture for im-
munological evaluation, the procedures and possible hazards
to which he/she will be exposed and the mechanism of treat-
ment allocation. Patients are free to withdraw from the study
at any time without providing any specific reason. Further-
more, it is the responsibility of the investigator to explain to
patients their duties within the trial. They will be informed
about the strict confidentiality of their patient data but that
their medical records may be reviewed for trial purposes by
authorized individuals other than their treating physician.
Trial insurance
This trial is comparing two standard treatments that repre-
sent current medical practice in Austria. No experimentaltreatment is delivered to patients within this trial. The trial
is not subject to the Austrian Drug Law and may be con-
sidered as a so-called ‘free’ clinical study, for which no legal
requirements exist concerning patient indemnity insu-
rance. This trial is regulated by the Austrian Medical
Device Law § 40.5. The sponsor has procured public liabi-
lity insurance from the Sisters of Charity Hospital Linz
that covers the conduct of clinical trials.
Statistical considerations
From a statistical point of view the present trial shows a
confirmatory status, superiority approach and a parallel
group design (group A with AirSeal™ use versus group S
with standard CO2 pressure pneumoperitoneum insufflator
use). The type I error preservation by the gatekeeping ap-
proach (primary endpoint one: time of surgery (in minutes)
and primary endpoint two: shoulder pain at 48 hours after
end of surgery (measured using VAS)) was calculated.
Stratification according to the type of surgery was done.
Sample size estimation
On the basis of a comparison of two proportions, a sample
size of 182 (n = 91 per group) is needed to have 80% power
at a 5% significance level, assuming a dropout rate of 5%.
Data, assumptions and conditions are: type I error
(2.5% one-sided), type II error (20%), non-parametric
test (Mann–Whitney U-test), n (group A): n (group S)
(ratio of 1:1) and per-protocol analysis:
group A mean  standard deviationð Þ : 74; 8  41; 3 min
group S mean  standard deviationð Þ : 93; 5  41; 3 min gΔ ¼ 20%
ð1Þ
Analysis populations
The intention-to-treat (ITT) population: all subjects in
whom the use of AirSeal™ or a standard CO2 pressure
pneumoperitoneum insufflator has already begun will be
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lyzed. The ITT population will be used for the primary
safety evaluation of implantation (ITT analysis).
The per-protocol (PP) population will be: all subjects
without occurrence of dropout situation (all valid cases)
will be included in the PP population. All variables will
be analyzed. The PP population will be used for the
primary efficacy evaluation (PP analysis).Handling of implausible values and missing values
Implausible values have to be identified by the clinical
investigator. They will be converted into missing values.
Missing values will not be replaced, with the following
exception: missing values at the two primary endpoints
will be replaced by the mean of all plausible data (both
groups) of the respective endpoint. The missing-value
replacement procedure described above will be only
applied to the ITT analyses (no replacement of missing
values in the PP analysis).Statistical methods
The estimation of effect size for selected variables will
be the calculation of two-sided 95% confidence intervals.
Primary endpoint one will be set due to the clear
duration difference between colorectal surgery and the
other types of surgery (laparoscopic cholecystectomy
and laparoscopic hernia repair) a normal distribution of
the data can be excluded. Therefore, a nonparametric
test, namely the exact Mann–Whitney U-test will be
used (type I error = 2.5% one-sided).
Primary endpoint two (only if H0PE1 is rejected), will
be set by checking data sets for normal distribution (test
of normality: Kolmogorov-Smirnov with Lilliefors signifi-
cance correction, type I error = 5%). In the case of nor-
mal distribution the t-test for independent samples with
correction for heteroscedasticity (Levene’s test, type I
error = 5%) will be applied. In the case of a significant
deviation from the normal distribution the exact Mann–
Whitney U test will be used instead. In both cases the
type I error will be 2.5% one sided.
Metric variables data sets will be checked for normal
distribution (test of normality: Kolmogorov-Smirnov
with Lilliefors significance correction, type I error = 5%).
Normally distributed data sets will be compared between
the groups by the t-test for independent samples with
correction for heteroscedasticity (Levene’s test, type I
error = 5%). If there is a significant deviation from the
normal distribution the exact Mann–Whitney U test will
be used instead.
Ordinal variables will be checked by the exact Mann–Whitney
U test and nominal variables by the exact chi-square
homogeneity test or, for 2 × 2 frequency tables the Fisher's
exact test.All tests will be two-sided with a confidence level of
95% (P <0.05). As no adjustment of the P values will be
made, the resulting P values will only be descriptive.
Presentation of the results (descriptive analysis
and graphs)
Nominal variables will be presented using counts and per-
centages. Ordinal variables will be presented using counts
and percentages (where appropriate) or minimum, 25% per-
centile, median, 75% percentile and maximum and number
of patients (where appropriate). Metric variables will be pre-
sented using minimum, 25% percentile, arithmetic mean,
median, 75% percentile, maximum, standard deviation and
number of patients. All results will be presented in the form
of tables, selected results additionally in the form of graphs
(bar charts and boxplots). Subgroup analyses can be
performed for cause, however, all statistical results will be
only descriptive. No interim analysis is intended.
Discussion
Many physiological changes occur during CO2 pneumo-
peritoneum. The severity of these pathophysiological dis-
turbances depends on the intra-abdominal pressure being
used and patients´ exposure to CO2 pneumoperitoneum,
hence on operation time. Post-laparoscopic shoulder pain
one to three days after laparoscopy is well described [15].
There have been few reports comparing low and high
pressure pneumoperitoneum, demonstrating that low
pressure was associated with lower postoperative inci-
dence of shoulder pain [16,17], while others have shown
that pressure had less effect on pain [18]. AirSeal™, a novel
class of valve-free insufflation system, works by a pres-
sured gas barrier of forced insufflation rather than the
trapdoor valves used by standard insufflators [19] which,
in a non-randomized clinical study in patients undergoing
laparoscopic renal surgery, was reported to be associated
with less carbon dioxide use, decreased blood loss and
shorter operation time than traditional insufflation [20].
The maintenance of pneumoperitoneum during changes
in equilibrium may be a factor during critical moments,
such as active bleeding. Within this trial we will evaluate
the potential clinical advantages and benefits of AirSeal™
in patients selected for elective laparoscopic cholecystec-
tomy, colorectal surgery or hernia repair.
Trial status
This trial is currently recruiting. The last patient is
expected to be fully recruited by March 2014.Additional file
Additional file 1: Study flow of the trial according to CONSORT
guidelines.
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